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Background: Vascular endothelial growth factor (VEGF) is known to be associated with the pathogenesis
of chronic rhinosinusitis with nasal polyps (CRSwNP). VEGF is produced by a variety of cells including
ﬁbroblasts. It was recently reported that prostaglandin (PG) E2 induces VEGF release by nasal polyp ﬁ-
broblasts. However, little is known regarding possible regulation of VEGF by other PGs. We have reported
that molecules that regulate PGD2 metabolism play roles in the pathogenesis of CRS including in local
eosinophilia and type 2 cytokine production. In the present study, we sought to determine whether PGD2
regulates VEGF release by nasal polyp ﬁbroblasts.
Methods: Nasal polyp ﬁbroblasts were established from nasal polyps. These ﬁbroblasts were stimulated
with serial dilutions of PGD2 or PGD2 receptor (DP/CRTH2)-selective agonists in the presence or absence
of receptor-selective antagonists. The concentration of VEGF in the culture supernatants was determined
using ELISA.
Results: 5 mM of PGD2 signiﬁcantly induced VEGF release by nasal polyp ﬁbroblasts. VEGF release was
also obtained by stimulation with a DP receptor-selective, but not with a CRTH2 receptor-selective
agonist. In addition, PGD2-induced VEGF release was signiﬁcantly inhibited by pre-treatment with DP
receptor-selective antagonists. In contrast, pre-treatment with a CRTH2 receptor-selective antagonist
signiﬁcantly enhanced PGD2-induced VEGF release.
Conclusions: PGD2 stimulates VEGF production via DP but not CRTH2 receptors in nasal polyp ﬁbroblasts.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vascular endothelial growth factor (VEGF) induces a variety of
functions including angiogenesis and vascular hyper-permeability,
and it is thought to be associated with the pathogenesis of chronic
rhinosinusitis with nasal polyps (CRSwNP).1e3 In NP, VEGF is mainly
expressed in vascular endothelial cells, basal membranes, peri-
vascular spaces, and epithelial cells.1 VEGF drives the proliferation
and survival of NP epithelial cells.2 The level of VEGF protein in nasal
lavage is signiﬁcantly higher in patients with CRSwNP as compared
with control subjects, and the serum level of VEGF is signiﬁcantly
increased during acute exacerbation in those patients.2,3ology-Head & Neck Surgery,
entistry and Pharmaceutical
.
kano).
ety of Allergology.
rgology. Production and hosting by ElseIn addition to VEGF expression in NP epithelial cells, NP-derived
ﬁbroblasts (NPDF) produce VEGF in response to various stimuli
such as hypoxia, TNF-a, LPS, and rhinovirus.4e6 Macrolides and
corticosteroids inhibit such VEGF production.4,6 More recently, it
was reported that prostaglandin (PG) E2, one of the major PGs
detected in NP, promotes VEGF release by NPDF via EP2 and EP4
receptors.7e9 However, little is known regardingwhether other PGs
might also regulate VEGF release.
PGD2 is another major PG associated with the pathogenesis of
CRSwNP.7,8,10 For example, we have shown that the level of PGD2 in
middle meatus secretions is signiﬁcantly higher in CRS patients
with NPs than in those without NPs.11 The mRNA level of
haemopoietic-type PGD2 synthase in NP was also signiﬁcantly and
positively correlated with the degree of NP eosinophilia and the
radiological severity of CRS.10 In addition, we have observed that
this synthase was expressed in inﬁltrating c-kitþ and vimentinþ
cells in NP, suggesting that mast cells and ﬁbroblasts are the
dominant sources of PGD2 release in CRS (unpublished data).vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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molecule expressed on Th2 cells (CRTH2) are the two major re-
ceptors reported for PGD2 to date.12 The DP receptor couples to the
Gs protein, and signaling through the DP receptor is known to
result in both pro-inﬂammatory and anti-inﬂammatory effects on
airway inﬂammation.10,13e16 On the other hand, the CRTH2 receptor
couples to the Gi protein, and signaling through CRTH2 mainly
shows a pro-inﬂammatory effect.17e19 In terms of the relationship
between PGD2 receptor expression and the pathogenesis of
CRSwNP, we have previously shown that the amount of mRNA for
eotaxin, which selectively induces eosinophil chemotaxis, signiﬁ-
cantly and positively correlated with the amount of the mRNA for
the DP receptor but not for the CRTH2 receptor in sinonasal
tissues.11
In the present study, we sought to determine whether PGD2
regulates VEGF release by NPDF, and if so, which PGD2 receptor
might mediate such release.Methods
Reagents
We purchased the following study materials: RPMI-1640, L-
glutamine-penicillin-streptomycin solution, protease, collagenase,
hyaluronidase, DNase I, FCS, trypsin, EDTA (all from Sigma, St. Louis,
MO, USA), and red blood cell lysis buffer (Roche, Indianapolis, IN,
USA). PGD2, receptor-selective agonists for DP (BW245C) and
CRTH2 (DK-PGD2), and a DP receptor-selective antagonist (MK-
0524) were purchased from Cayman (Ann Arbor, MI, USA). A CRTH2
receptor-selective antagonist (OC000459) was purchased from
ChemScene LLC (Monmouth Junction, NJ, USA). Another DP
receptor-selective antagonist, ONO-4053, was provided by Ono
Pharmaceuticals (Osaka, Japan). PGD2 and receptor-selective ago-
nists/antagonists were dissolved in DMSO (Sigma) to a stock con-
centration of 2  102 M (PGD2) or 2  103 M (others), ﬁltered
through a 0.2 mm ﬁlter, and stored at 80 C until use.Subjects
The study involved 28 Japanese CRSwNP patients (Table 1). The
presence of CRSwNP was determined based upon diagnostic
criteria reported in a European position paper on rhinosinusitis
and nasal polyps.20 All patients failed to respond to medical
treatment, including macrolide therapy, and thus received endo-
scopic sinus surgery. Among these, 7 and 21 patients were diag-
nosed into non-eosinophilic CRS (non-ECRS) and eosinophilic CRS
(ECRS), respectively, based on the JESREC (Japanese Survey of
Refractory Eosinophilic Chronic Rhinosinusitis) criterion.21 For at
least four weeks prior to surgery none of the participants received
systemic glucocorticoids, and for at least two weeks prior toTable 1
Subjects background.
Number 28
Sex (male:female) 18:10
Age (y) 56.1 ± 14.7
Age range (y) 27e80
Patients with bronchial asthma 12
Patients with allergic rhinitis 9
Serum IgE (IU/ml) 325 ± 438
Blood eosinophilia (% of white blood cell) 6.7 ± 4.7
CT grading score (LundeMackay system) 15.9 ± 5.2
FEV1/FVC ratio 74.7 ± 11.5
Results are shown as mean ± standard deviation.
FEV1/FVC, forced expiratory volume in one second/forced vital capacity.surgery none of the participants received pharmacotherapy for
rhinosinusitis, such as macrolide antibiotics or intranasal steroids.
Informed consent for participation in the study was obtained from
each patient, and the study was approved by the Human Research
Committee of the Okayama University Graduate School of Medi-
cine and Dentistry.
Generation of NPDF
NPDFwere generated as previously reported.22 Brieﬂy, NPswere
dispersed by enzymatic digestion using protease, collagenase, hy-
aluronidase, and DNase. The dispersed NP cells were suspended
with culture medium (RPMI 1640 supplemented with 10% FCS,
2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin)
in a culture dish (Sumitomo Bakelite, Tokyo, Japan) at 37 C ad 5%
CO2 for 10 days, and then non-adherent cells were removed by
changing the culture medium. After reaching conﬂuence, NPDF
were harvested by treatment with 0.25% trypsin and 0.02% EDTA,
and were then divided into new dishes. The cellularity of NPDF was
characterized using immunohistochemistry; more than 95% of
conﬂuent cells were found to be vimentin-positive. NPDF were
used after 6 to 8 passages.
Cell culture
NPDF were seeded into 48-well culture plates (Asahi Techno
Glass, Tokyo, Japan). When the cells reached conﬂuence, they were
rested in medium containing 0.5% FCS for 4 days. The cells were
then stimulated with serial dilutions (0.5, 5.0, or 50 mM) of PGD2
or control buffer (DMSO) for 24 or 72 h. In order to determine
receptor speciﬁcity, serial dilutions (0.1, 1.0, or 10 mM) of BW245C,
DK-PGD2, or control buffer were added for 72 h. Alternatively,
serial dilutions (0.1, 1.0, or 10 mM) of DP receptor-selective an-
tagonists (MK0524 or ONO-4053) or a CRTH2 receptor-selective
antagonist (OC0000459) were added to NPDF treated with 5 mM
of PGD2 for 72 h.
Measurement of VEGF
The levels of VEGF were determined using a DuoSet™ ELISA
development kit (R&D Systems, Minneapolis, MN, USA). The
detection limit was 8 pg/mL.
Real-time quantitative PCR
Real-time quantitative PCR for analysis of the mRNA level of DP
and CRTH2 receptors in NPDF was performed as described previ-
ously.11 Levels of VEGF mRNA in NPDF following exposure to 5 mM
PGD2 or control buffer (0.25% DMSO) for 2 h were also deter-
mined. The primers designed for VEGF determination had the
following sequences: forward 50-TGCAGATTATGCGGATCAAACC-30
and reverse 50-TGCATTCACATTTGTTGTGCTGTAG-3’ (81 bp).23 The
absolute copy number for each sample was calculated, and sam-
ples are reported as copy number relative to GAPDH mRNA that
was used as an internal control. RT-PCR for GAPDH, DP and CRTH2
were also performed, and gel images using 2% agarose were
developed.
Statistical analysis
Values are given as the median. The nonparametric Wilcoxon's
signed rank test was used to analyze data. P-values less than 0.05
were considered statistically signiﬁcant. Statistical analyses were
performed using SPSS software (version 11.0, Chicago, IL, USA).
Fig. 2. PGD2-induced VEGF mRNA expression by NPDF. NPDF were stimulated with
5 mM PGD2 or control buffer (0.25% DMSO) for 2 h. Relative amounts of VEGF mRNA in
NPDF were determined by real-time quantitative PCR. Bar represents median. P-values
were determined using the Wilcoxon signed-rank test.
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Effect of PGD2 on VEGF release by NPDF
As compared to control (0.25% DMSO), a signiﬁcant increase in
the production of VEGF protein was seen following both 24-h
(P ¼ 0.038, n ¼ 9) and 72-h (P ¼ 0.008) stimulation of NPDF with
5 mM of PGD2 (Fig. 1). The levels of VEGF were signiﬁcantly higher
after 72-h stimulation as compared with after 24-h stimulation
(P ¼ 0.011). Therefore, for further investigation, we stimulated
NPDF with PGD2 or receptor-selective agonists for 72 h. No signif-
icant difference in 5 mM PGD2-induced VEGF production by NPDF
(n ¼ 25) was seen between ECRS (n ¼ 7) and non-ECRS (n ¼ 18)
patients (P ¼ 0.856). Moreover, the presence of asthma (P ¼ 0.542)
or allergic rhinitis (P ¼ 0.533) had no impact on VEGF release.
Similar to the protein level, mRNA expression of VEGF was also
increased following exposure to PGD2 (P ¼ 0.043, n ¼ 5) (Fig. 2).
Effect of PGD2 receptor-selective agonists on VEGF release by NPDF
To evaluate the receptor speciﬁcity of PGD2 stimulation of VEGF
release, we stimulated NPDF with PGD2 receptor-selective agonists.
A signiﬁcant release of VEGF was obtained by stimulation with the
DP receptor-selective agonist, BW245C, in a dose-dependent
manner (P ¼ 0.011, n ¼ 8) (Fig. 3A). In contrast, no signiﬁcant
VEGF release was seen following stimulation with the CRTH2
receptor-selective agonist, DK-PGD2 (Fig. 3B). Instead, a trend of
inhibition of VEGF release was seen in response to 10 mM of DK-
PGD2 (P ¼ 0.093).
Effect of receptor-selective antagonists on PGD2-induced VEGF
release by NPDF
To conﬁrm the above receptor speciﬁcity of PGD2 in VEGF
stimulation, PGD2-stimulated NPDF were treated with receptor-
selective antagonists. As compared with control (0.25% DMSO),
MK-0524 and ONO-4053, both of which are DP receptor-selective
antagonists, inhibited PGD2-induced release of VEGF in a dose-
dependent manner. The maximum inhibition (34.9% and 46.6%
for MK-0524 and ONO-4053, respectively) was seen at an antago-
nist concentration of 10 mM (P ¼ 0.018, n ¼ 7). In addition, signif-
icant inhibition was seen following treatment with ONO-4053
(P ¼ 0.028) but not with MK-0524 (P ¼ 0.091) at a concentration
of 0.1 mM (Fig. 4). On the other hand, treatment with the CRTH2Fig. 1. PGD2-induced VEGF protein production by NPDF. NPDF were stimulated with a seri
rectangle includes the range from the 25th to 75th percentiles; the horizontal line indicates t
values were determined using the Wilcoxon signed-rank test.receptor antagonist, OC000459, did not inhibit the VEGF release
induced by PGD2. Instead, this treatment signiﬁcantly augmented
VEGF release at concentrations of 1.0 (P ¼ 0.004, n ¼ 11) and 10
(P ¼ 0.006) mM (Fig. 5).
Quantiﬁcation of DP/CRTH2 mRNA in NPDF
Real-time PCR revealed that the level of DP receptor mRNA in
NPDFwas signiﬁcantly higher than that of CRTH2mRNA (P¼ 0.008,
n ¼ 9) (Fig. 6A). Gel images by RT-PCR conﬁrmed dominant
expression of DP mRNA in NPDF (n ¼ 5) (Fig. 6B).
Discussion
In the present study, we examined the effect of PGD2 on VEGF
release by NPDF. We found for the ﬁrst time that NPDF produced
VEGF in response to 5 mM of PGD2. Little is known regarding
whether PGD2 induces VEGF production in humans. One report
showed that PGD2 induced VEGF mRNA expression in human
retinal capillary pericytes through activation of adenylate cyclase.24
Our results were consistent with this report, and suggest that not
only pericytes but also ﬁbroblasts produce VEGF in humans in
response to PGD2. Several factors such as hypoxia, TNF-a, LPS,
rhinovirus and PGE2 can induce VEGF release by NPDF.4e6,9 The
amount of VEGF protein in response to PGD2 is comparable to that
in response to hypoxia, TNF-a, LPS and PGE2. Together with theal concentration of PGD2 or control buffer (0.25% DMSO) for 24 h (A) or 72 h (B). The
he median, and the vertical line indicates the range from the 10th to 90th percentiles. P-
Fig. 3. Effect of PGD2 receptor-selective agonists on VEGF release by NPDF. NPDF were stimulated with a serial concentration of BW245C (A) or DK-PGD2 (B) for 72 h. The rectangle
includes the range from the 25th to 75th percentiles; the horizontal line indicates the median, and the vertical line indicates the range from the 10th to 90th percentiles. P-values
were determined using the Wilcoxon signed-rank test.
Fig. 4. Effect of DP receptor-selective antagonists on PGD2-induced VEGF release by NPDF. NPDF were stimulated with 5 mM PGD2 in the presence or absence of a serial con-
centration of MK-0524 (A) or ONO-4053 (B) for 72 h. The rectangle includes the range from the 25th to 75th percentiles; the horizontal line indicates the median, and the vertical
line indicates the range from the 10th to 90th percentiles. P-values were determined using the Wilcoxon signed-rank test.
Fig. 5. Effect of CRTH2 receptor-selective antagonist on PGD2-induced VEGF release by
NPDF. NPDF were stimulated with 5 mM PGD2 in the presence or absence of a serial
concentration of OC000459 for 72 h. The rectangle includes the range from the 25th to
75th percentiles; the horizontal line indicates the median, and the vertical line in-
dicates the range from the 10th to 90th percentiles. P-values were determined using
the Wilcoxon signed-rank test.
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meatus of patients with CRSwNP,11 PGD2 may be one of the
dominant factors of increasing VEGF in CRSwNP.
Stimulation with BW245C but not with DK-PGD2 mimicked the
effect of PGD2 on VEGF release by NPDF. In addition, treatment with
MK0524 and ONO-4053 but not with OC000459 signiﬁcantly
abrogated the effect of PGD2. These ﬁndings suggest that PGD2
induced VEGF release via the DP receptor and not via the CRTH2
receptor in NPDF. This selective release through the DP receptor
may be due to the predominant expression of the DP receptor over
that of the CRTH2 receptor in NPDF as shown using real-time PCR.
The predominant expression of the DP receptor is consistent with
our previous report showing that the DP receptor is expressed by a
variety of cells including constitutive cells and inﬁltrating inﬂam-
matory cells, whereas the CRTH2 receptor is mainly expressed by
inﬁltrated inﬂammatory cells in NP.11
No signiﬁcant difference in PGD2-induced VEGF production by
NPDF was seen between ECRS and non-ECRS patients. We previ-
ously reported that mRNA level of DP in sinonasal tissues signiﬁ-
cantly correlated with that of eotaxin but not IL-5 or RANTES.11 We
also have found that the mRNA levels of DP did not correlate with
Fig. 6. Relative amounts of DP and CRTH2 receptor mRNA in NPDF. (A) Real-time
quantitative PCR. The absolute copy number for each sample was calculated, and
samples were reported copy number relative to GAPDH used to be an internal control.
The rectangle includes the range from the 25th to 75th percentiles; the horizontal line
indicates the median, and the vertical line indicates the range from the 10th to 90th
percentiles. P-values were determined using the Wilcoxon signed-rank test. (B) RT-
PCR. Gel images of mRNA expressions of GAPDH, DP and CRTH2 in NPDF were
shown (n ¼ 5). M, molecular weight marker.
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suggest that VEGF has more activities than eosinophilic inﬂam-
mation in the pathogenesis of CRSwNP.
It is known that PGE2 promotes VEGF release by NPDF via EP2
and EP4 receptors.9 Although unbalanced expression of PGD2 and
PGE2 is associated with the pathogenesis of CRSwNP, both PGD2
and PGE2 can promote VEGF release by NPDF.8,10 This ﬁnding is not
surprising since both DP and EP2/EP4 receptors couple to the Gs
protein, which activates adenylate cyclase.9,12 It is known that
signaling through adenylate cyclase/protein kinase A enhances
VEGF release by ﬁbroblasts.25,26 Thus our results support previous
ﬁndings and may suggest that activation of adenylate cyclase by
PGD2 also promotes VEGF release by ﬁbroblasts.
Both MK-0524 and ONO-4053 abrogated PGD2-induced VEGF
release by NPDF in a dose-dependent manner. ONO-4053 but not
MK-0524 showed signiﬁcant abrogation at a concentration of
0.1 mM, suggesting that PGD2 antagonism of ONO-4053 is more
potent than that of MK-0524. On the other hand, it should be noted
that both of these antagonist showed partial inhibition. There are
two possible explanations of this partial inhibition. First, PGD2 is
known to couple not only to DP and CRTH2 receptors but also to TP
and EP3 receptors.12 Indeed, signaling through the TP receptor
promotes VEGF release in human lung cancer cell lines.27 However,
MK-0524 can act as a TP antagonist, and therefore an effect of TP
signaling on the observed partial inhibition is unlikely.28 It is also
unlikely that EP3 mediates VEGF release by NPDF since a previous
report showed that sulprostone, an EP1/EP3 receptor agonist, did
not induce VEGF release byNPDF.9 In addition, EP3 couples to the Gi
protein and inhibits adenylate cyclase.29 The second possible
explanation of the observed partial inhibition is that there might be
an effect of 15-deoxy-D12,14-PGJ2, which is a derivative of PGD2 that
is known to function as a ligand of peroxisome proliferator-
activated receptor (PPAR)-g.12 Although little is known regarding
whether 15-deoxy-D12,14-PGJ2 promotes VEGF release by ﬁbro-
blasts, vascular endothelial cells and cardiac myoﬁbroblasts can
release VEGF in response to 15-deoxy-D12,14-PGJ2.30,31 The effects of15-deoxy-D12,14-PGJ2 and/or PPAR-g on PGD2-induced VEGF release
by NPDF should be investigated in the future.
Interestingly, treatment with OC00045 signiﬁcantly augmented
PGD2-induced VEGF release by NPDF. An opposing role of DP and
CRTH2 receptors can be seen in various conditions such as skin
inﬂammation and ulcerative colitis.32e34 For example, treatment
with DP receptor-selective agonists inhibited CRTH2 receptor-
induced chemotaxis of human eosinophils.32 In the present study,
although not signiﬁcant, treatment with 10 mM of DK-PGD2 tended
to inhibit VEGF release by NPDF. These results suggest that signals
through the CRTH2 receptor regulate the effect of DP receptor
signaling on VEGF release, and that blockage of CRTH2 receptor
signaling augments DP receptor signaling, which then enhances
VEGF release in NPDF. The lack of dose-dependent effect by PGD2
but not DP receptor-selective agonist on VEGF release may be due
to the stimulation of CRTH2 receptor by high concentration of
PGD2.
NPDF may produce many other cytokines and extracellular
matrix involved in the pathogenesis of CRS. In fact, our preliminary
result suggests that PGD2 signiﬁcantly induces IL-6 and IL-8 but not
TGF-b by NPDF. Determining how PGD2 promotes the release cy-
tokines and extracellular matrix other than VEGF by NPDF should
be investigated in future studies.
In conclusion, the present study shows that PGD2 promotes
VEGF release from NPDF via the DP receptor. This result suggests
the therapeutic potential of DP receptor-selective antagonists for
prevention of edema formation and/or angiogenesis mediated by
VEGF in CRSwNP.
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